Tag: adverse events
-
Ozempic, Wegovy, Other GLP-1 Semaglutide Weight-Loss Drugs Linked to Gastroparesis in Recent Medical Study
Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients (Posted by Tom Lamb at Drug Injury Watch) An October 2023 medical journal article presented the results of…
-
Novartis Update on Patients Suffering from Retinal Vasculitis and/or Retinal Vascular Occlusion After Beovu Injections
November 2020 Report: Beovu Eye Side Effects Risks Higher for Beovu Patients with Prior Intraocular Inflammation and/or Vascular Occlusion (Posted by Tom Lamb at DrugInjuryWatch.com) We have known since early 2020 that…
-
Ocaliva FDA Adverse Events Reports for Hepatobiliary System Cases: An Analysis as of October 2020
Lack of Warnings in Current Ocaliva Drug Label for Some Serious Side Effects Involving Liver, Gallbladder, Bile Ducts (Posted by Tom Lamb at DrugInjuryWatch.com) We are still wondering how the current FDA…
-
Lemtrada Adverse Events May Occur More Frequently Than Previously Noted By Drug Safety Regulators And Researchers
Ten Deaths Identified As Being Most Probably Related To Lemtrada, With Six Of These Cases Not Previously Reported, According To New Study (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Dear Healthcare Professional…
-
Tasigna Side Effects Include Ischemic Cerebrovascular Events, Ischemic Heart Disease, And Peripheral Arterial Occlusive Disease
Less Warning About These Atherosclerosis-Related Diseases By Novartis In The US, It Seems, Compared To What Has Been Done By The Drug Company In Canada (Posted by Tom Lamb at DrugInjuryWatch.com) Tasigna…
-
Keytruda, Opdivo, And Yervoy May Be Associated With Vision Loss And Retinal Detachment In Addition To Uveitis
In June 2017 The FDA Announced It Is Evaluating Possible Drug Label Changes And The Need For Other Regulatory Actions (Posted by Tom Lamb at DrugInjuryWatch.com) According to the document “Potential Signals…
-
Possible Linzess Recall By FDA Suggested By Phase Five Research Analyst Report, Which Has Become A Bit Of A Mystery
Here Are Some Of The "Findings" From An April 26, 2016 Document Which Seems To Have Disappeared Only Two Days Later (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Synergy Petitions FDA…
-
Possible Linzess Recall By FDA Suggested By Phase Five Research Analyst Report, Which Has Become A Bit Of A Mystery
Here Are Some Of The "Findings" From An April 26, 2016 Document Which Seems To Have Disappeared Only Two Days Later (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Synergy Petitions FDA…
-
Xolair Is Associated With Higher Than Expected Reporting Of Arterial Thrombotic Events Such As Strokes And Cardiovascular Deaths
While European Drug Regulators Have Been Concerned About This Aspect Of Xolair Safety, FDA Has No Warning About Arteriothrombotic Risks Of Xolair (Posted by Tom Lamb at DrugInjuryWatch.com)In September 2014 the FDA issued an update about its…
-
Omontys-Related Adverse Reactions And Deaths Update: Are There More Cases Than Initially Disclosed
FDA Adverse Event Report For Omontys Reveals Affymax And Takeda May Have Downplayed Magnitude Of Problems (Posted by Tom Lamb at DrugInjuryWatch.com) When the dialysis – anemia medication Omontys was recalled in February 2013 it…